Monterrey

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Lung cancer2 trials
• Asthma1 trial
• COPD1 trial
• Head and neck cancer1 trial
• HIV1 trial
• Primary biliary cholangitis1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 37 trials
• Phase 2/31 trial

Status

• Active, not recruiting4 trials
• Completed3 trials
• Recruiting1 trial

Lead sponsor

• GlaxoSmithKline7 trials
• ViiV Healthcare1 trial

Running trials

• Recruiting

  A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

  NCT06256588· Phase 3· GlaxoSmithKline· Source

  Contact: Mario Alberto Sánchez Prieto (principal investigator)

• Active, not recruiting

  A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

  NCT05757102· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

  NCT04915755· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

  NCT04655976· Phase 2/3· GlaxoSmithKline· Source

• Active, not recruiting

  Linerixibat Long-term Safety, and Tolerability Study

  NCT04167358· Phase 3· GlaxoSmithKline· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Head and neck cancer1 recruiting

Closed trials

• Completed

  A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

  NCT05911360· Phase 3· ViiV Healthcare· Source

• Completed

  Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer

  NCT04475939· Phase 3· GlaxoSmithKline· Source

• Completed

  Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

  NCT04133909· Phase 3· GlaxoSmithKline· Source